Alzheimer’s agitation trial adds Mount Sinai with 80% of patients finished
IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a new clinical site for its Phase 2 CALMA trial of IGC-AD1, which targets agitatio...
IGC
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (2)
Neutral (0)
Bearish (0)
Latest IGC News
Bullish
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma announced the addition of Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's diseas...
Research IGC on:
Ad Space